“We aim to positively impact life and health with science, and today’s unprecedented achievement is based on this by adding physical efficiencies and expanding our regional network to meet the growing needs of our customers and ensure supply chain security. An example of commitment,” said Mathias Henzel, member of the Executive Board of Merck KGA and CEO Life Sciences. “This new, state-of-the-art facility will support the growth in demand experienced by our global in-vitro diagnostic manufacturing customers.”
The Governor of Wisconsin, Tony Evers, said, “From COVID-19 rapid testing to cancer therapy, the work MilliporeSigma does is helping to promote the health and safety of our families and communities while creating decent jobs for hardworking Wisconsinians. And I’m pleased to celebrate their success today. In addition to creating 60 new jobs at Sheboygan, this new facility will provide a major step forward in expanding in-house clinical testing as the company operates in the US. Our first lateral flow membrane production facility, ensures that our state and country are prepared to deal with any public health crisis that comes our way now and in the future.”
Once built, the Lateral Flow Membrane Facility will be MilliporeSigma’s first facility in the US capable of producing diagnostic-grade membranes. Its location supports the company’s competitive market advantage with superior supply security and low Chief Time for global customers. The lateral flow membrane production line in Sheboygan complements the life science business sector’s global capacity network of Merck KGA, Darmstadt, Germany, by adding redundant efficiencies across its two production lines in Cork, Ireland, thereby reducing supply chain risk .
“This new facility will expand much-needed access to critical raw materials for the world’s most sophisticated diagnostic manufacturers. Our best-in-class lateral flow membranes deliver quality and consistency as manufacturers prepare for in-vitro diagnostics and therapy. Let’s prepare for the new regulations. Instruments,” said Jean-Charles Wirth, head of life sciences business, science and laboratory solutions, at Merck KGA.
Hi-Flow Plus Lateral Flow Membrane enables reproducible results due to its consistent quality and optimized properties. Rapid point-of-care test kits developed by the company’s customers are used for a variety of applications, including infectious disease testing (eg, COVID-19, HIV, influenza, malaria) as well as pregnancy tests, biomarkers detection is included. Drug testing, food safety and animal health.
